Leverage community oncology insights to strengthen your market access strategy

Community oncology practices play a critical role in the cancer care landscape, providing access to cancer care outside of large academic centers and integrated delivery networks. With a focus on delivering personalized care close to home, these practices are essential to ensuring that cancer therapies reach broader patient populations. The number of oncologists practicing in the community is shrinking while demand for localized, patient-centric care continues to grow, leading providers to seek new and more sophisticated organizational solutions.  Understanding the dynamics of community oncology is vital for biopharma companies looking to optimize access to their therapies.

Our research delves into the operational and clinical strategies that drive community oncology practices, helping biopharma companies align their market access efforts with the specific needs of these increasingly hard-to engage providers. From understanding treatment patterns to navigating payer relationships, our insights help you stay ahead of the curve in this critical segment.

Unlock strategic insights into IDNs to optimize Your market access approach

Integrated Delivery Networks (IDNs) are a vital and growing segment of the modern healthcare ecosystem. Over the last several years, IDNs have continued to integrate care into complex systems that are changing the way care is delivered. As these organizations continue to expand, IDNs have a significant and growing impact on drug utilization and access, making them a crucial focus for biopharmaceutical companies.
We recognize IDNs as a primary research segment due to their growing influence on market access strategies, especially within oncology. Understanding how IDNs operate is key to successfully navigating drug access barriers.
Our in-depth research into IDNs provides biopharma companies with actionable insights into how these networks function, how decisions are made, and how market access can be optimized within these systems. Whether you're looking to understand the latest trends in IDN growth, access strategy, or the impact of IDN decisions on oncology drug utilization, we deliver the data and insights you need to stay ahead.

Accessing success

In 2024, 75% of health plan and PBM executives claim they will use step therapies and exclusions significantly more over the next two years to control utilization and the cost of cancer drugs.   That said, we’ve heard this before. So, will private health plans and PBMs ACTUALLY ratchet down on oncology drugs and force manufacturers into steeper rebates in the near future? Maybe, but not universally and regardless, they already have some level of direct and indirect influence.  
This is why private payers are one of MARIN’s core research segments. In addition to studying HOW payers are currently attempting to control cancer costs and plan to over the next few years, we also seek to understand WHAT could change in the market that would empower them to do so. Legislative changes, crowding drug classes and employer readiness to adopt new strategies are a few “tipping point dynamics” that can put payer oncology management on a new trajectory.  MARIN’s Payer Insights practice engages the right people to scope out these uncertainties, deciphers noise from facts and constructs actionable insights for our biopharmaceutical clients.

From gaining insights into payer decision-making to navigating value-based environments, our deep dive into payers helps clients enhance their market access planning and strategies, meet the evolving demands of this influential stakeholder group and overcome barriers, all to support patient-centered success.